iVEAcare Neuromodulation System Study for Drug-Resistant Epilepsy Underway
A feasibility study is assessing the safety and performance of the iVEAcare Neuromodulation System in drug-resistant epilepsy patients.
Asset / Drug
Drug and asset intelligence for iVEAcare with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.